Total Body Irradiation + Tisagenlecleucel for B-Cell Lymphoma

This trial tests a new treatment for large B-cell lymphoma that has returned or resisted other treatments. It combines total body irradiation (a type of radiation therapy) and chemotherapy to prepare the body for an infusion of specially modified immune cells called CAR T-cells, which help the immune system attack cancer. The trial aims to determine the safest and most effective dose for this combination. People whose large B-cell lymphoma did not respond to at least two treatments might be suitable candidates. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

Research has shown that tisagenlecleucel, or Tisa-cel, has been safely used to treat certain blood cancers. This treatment, a type of CAR T-cell therapy, has received FDA approval for some conditions, indicating a recognized level of safety.

Earlier studies reported common side effects such as headache, dizziness, and sleep problems. More serious side effects, like cytokine release syndrome—which can cause fever and low blood pressure—occurred but were mostly manageable. Specifically, one study found that about 62% of patients experienced this condition.

Unlike the standard treatments for B-cell lymphoma, which typically include chemotherapy, radiation, or monoclonal antibodies, Tisagenlecleucel is a type of CAR T-cell therapy. This innovative approach involves modifying a patient's own T-cells to better recognize and attack cancer cells. Researchers are excited about Tisagenlecleucel because it offers a targeted attack on cancer cells, potentially leading to longer-lasting remissions compared to traditional therapies. Additionally, this treatment may provide an option for patients who have not responded well to other treatments, offering new hope for those with difficult-to-treat lymphoma.

Research has shown that tisagenlecleucel, a type of CAR T-cell therapy, holds promise for treating large B-cell lymphoma (LBCL). Studies have found that about 59.5% of patients respond to this treatment, with 44.5% experiencing a complete response, meaning their cancer became undetectable after treatment. This therapy modifies a patient's own T cells to better attack cancer cells. Tisagenlecleucel targets a protein called CD19 on cancer cells, enhancing the immune system's ability to destroy them. In this trial, participants will receive tisagenlecleucel combined with total body irradiation and lymphodepletion. Although the results are encouraging, further research is needed to confirm its effectiveness in this specific combination.¹⁶⁷⁸⁹